Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Ovarian Cancer
How do you manage a stage IC3 grade 2 endometrioid ovarian carcinoma in an otherwise healthy perimenopausal patient?
Related Questions
Do you routinely give prophylactic antibiotics/steroids for patients on MEK-inhibitors (e.g., trametinib) to prevent rash/dermatitis?
Would you hold a PARP inhibitor in the perioperative period for an ileostomy reversal in a patient who has completed primary debulking surgery followed by chemotherapy?
How have you incorporated mirvetuximab into the treatment of platinum-resistant ovarian cancer?
What hormonal therapy, if any, would you offer for adjuvant treatment of stage IC ER-/PR+ low grade serous ovarian cancer?
Do you recommend bevacizumab with front-line platinum-based adjuvant chemotherapy for fully resected stage III ovarian clear cell carcinoma?
Would you ever re-treat recurrent ovarian cancer with mirvetuximab soravtansine if the patient responded to it in the past (e.g., more than 6 months ago)?
In the absence of a cohesive workflow guiding the use of PARPi in ovarian cancer since the 2022 FDA approval withdrawals, what is your general approach to PARPi usage in the front-line and recurrent setting?
Would you prescribe vaginal estrogen cream for vaginal dryness to a patient in her 40s with a history of stage IA granulosa cell tumor?
What outcome data do you view as most impactful to make treatment decisions regarding the use of PARP inhibitors in later line or recurrent ovarian cancer?
How would you approach adjuvant therapy for a patient who was diagnosed with surgically staged and completely resected stage II high-grade serous ovarian cancer while she prepared for neoadjuvant chemoradiation for rectal cancer?
